Mathematical and experimental models of interactions among subclones and immunity in melanoma
Abstract
Melanoma tumors often contain heterogeneous subclones, typically with proliferative or invasive phenotypes. These subclones interact with each other and the immune system to shape tumor progression. Understanding interactions between subclones and the tumor microenvironment is a fundamental challenge for melanoma treatment. To analyze such interactions, we developed dedicated in vivo melanoma mouse and mathematical models. In the experimental models, admixtures of proliferative and invasive subclones of varying proportions were implanted into immunocompromised and immunocompetent mice. Tumor growth and subclone composition were tracked over time. In parallel, we built a computational model to capture the system dynamics. By estimating parameter values of our mathematical model using experimental measurements, we found that, while the proliferative subclone outgrew the invasive subclone, T cell activities selected for the invasive subclone. Initial subclonal proportion in this dynamic system determines the overall tumor sensitivity to immune response. The key interactions identified in this study provide insights into how intratumor heterogeneity and immune pressure influence melanoma progression, suggesting strategies for optimizing individualized therapy.
Related
- Astatine-211 injury induces an immunostimulatory melanoma-cell state and promotes systemic antitumor immunity
- Development of an Experimental Protocol for Combined Electroporation and Phototherapy Treatment Against Melanoma Cells
- Evidence of active whole-genome doubling (WGD) subclones in non-WGD tumors
- Experimental and mathematical models reveal that AMPK modulates circadian clock gene expression and period through NAD+-dependent regulation of Bmal1
- Enhancement of postpartum cow health and calf performance through maternal‒offspring interactions: effects on the immunity, antioxidants, and bacterial flora induced by Guiqi Yimu Powder
BibTeX
@article{hirsch2026mathematical,
title = {{Mathematical and experimental models of interactions among subclones and immunity in melanoma}},
author = {M. G. Hirsch and Jon C. Ergun and Sung Chin and Cari Graff and Danielle Yee and Eva Perez-Guijarro and Glenn Merlino and Chi-Ping Day and Teresa M. Przytycka},
journal = {Communications Biology},
year = {2026},
month = nov,
doi = {10.1038/s42003-026-11153-4},
url = {https://www.nature.com/articles/s42003-026-11153-4},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Mathematical and experimental models of interactions among subclones and immunity in melanoma
AU - M. G. Hirsch
AU - Jon C. Ergun
AU - Sung Chin
AU - Cari Graff
AU - Danielle Yee
AU - Eva Perez-Guijarro
AU - Glenn Merlino
AU - Chi-Ping Day
AU - Teresa M. Przytycka
PY - 2026
DA - 2026/11/03
JO - Communications Biology
DO - 10.1038/s42003-026-11153-4
UR - https://www.nature.com/articles/s42003-026-11153-4
AB - Melanoma tumors often contain heterogeneous subclones, typically with proliferative or invasive phenotypes. These subclones interact with each other and the immune system to shape tumor progression. Understanding interactions between subclones and the tumor microenvironment is a fundamental challenge for melanoma treatment. To analyze such interactions, we developed dedicated in vivo melanoma mouse and mathematical models. In the experimental models, admixtures of proliferative and invasive subclones of varying proportions were implanted into immunocompromised and immunocompetent mice. Tumor growth and subclone composition were tracked over time. In parallel, we built a computational model to capture the system dynamics. By estimating parameter values of our mathematical model using experimental measurements, we found that, while the proliferative subclone outgrew the invasive subclone, T cell activities selected for the invasive subclone. Initial subclonal proportion in this dynamic system determines the overall tumor sensitivity to immune response. The key interactions identified in this study provide insights into how intratumor heterogeneity and immune pressure influence melanoma progression, suggesting strategies for optimizing individualized therapy.
SN - 2399-3642
ER -